Investors Encouraged to Join Ultragenyx Securities Fraud Class Action with Schall Law Firm

Recently, the Schall Law Firm, a reputable national firm specializing in shareholder rights, has made an announcement reminding investors about a class action lawsuit against Ultragenyx Pharmaceutical Inc., a biotechnology company known for developing treatments for rare diseases. The lawsuit centers around allegations of securities fraud under the Securities Exchange Act of 1934, specifically violations of §§10(b) and 20(a), along with Rule 10b-5 enforced by the U.S. Securities and Exchange Commission.

Background of the Lawsuit

Eligible investors who acquired Ultragenyx's securities between August 3, 2023, and December 26, 2025, are encouraged to take action before the deadline of April 6, 2026. The lawsuit arises from claims that the company provided misleading information regarding its drug candidate's effects on patients suffering from Osteogenesis Imperfecta (OI). Investors assert that Ultragenyx's public statements during the class period painted an inaccurately optimistic picture, which ultimately led to significant investor losses when the truth was later revealed.

The class action lawsuit became necessary after the Phase III ORBIT study for Ultragenyx’s product failed to show a statistically significant reduction in annualized fracture rates, contradicting earlier assurances given to the market. Following this revelation, the company’s stock value plummeted, resulting in considerable financial damage to investors who acted on the false assurances.

What Investors Should Know

If you are a shareholder who experienced losses during the class period, participating in this lawsuit may provide an opportunity to recoup your financial damages. The Schall Law Firm has been actively representing investors globally, specializing in securities class action lawsuits and advocating for shareholder rights. They encourage affected individuals to reach out for a complimentary discussion about their legal rights and potential for recovery.

Investors can contact Brian Schall directly at the Schall Law Firm, located at 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, or by calling 310-301-3335. Additionally, the firm’s website, www.schallfirm.com, provides further information and methods for potential participants to get involved.

Next Steps for Participants

Although the class has not yet received certification, it’s critical for interested parties to act promptly. Should an investor choose not to join the action, they would remain an absent class member, thus potentially losing their opportunities to recover any losses incurred due to Ultragenyx's alleged misleading practices.

This legal development highlights the importance of awareness regarding investor rights and the need for vigilance in the information shared by biotechnology companies and other entities within the pharmaceutical sector. As the lawsuit progresses, affected investors are urged to remain informed and proactive on developments within the case.

In summary, if you have been adversely impacted by your investment in Ultragenyx during the designated timeframe, you are not alone. The Schall Law Firm is prepared to assist you in navigating the complexities of this case and advocating on your behalf to seek justice and recovery for the damages incurred.